Sanofi (LON:0A2V)

Market Cap	83.91B -22.9%
Revenue (ttm)	40.75B +5.5%
Net Income	6.82B +40.5%
EPS	5.56 +43.6%
Shares Out	n/a
PE Ratio	12.31
Forward PE	9.54
Dividend	1.20 (2.61%)
Ex-Dividend Date	May 9, 2025

Volume	1,668
Average Volume	97,013
Open	47.50
Previous Close	47.03
Day's Range	46.49 - 47.50
52-Week Range	44.39 - 60.08
Beta	0.40
RSI	47.55
Earnings Date	Jan 29, 2026

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 74,846
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A2V

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial numbers in EUR